knowledge -WSS

knowledge

author：comprehensive 2025-09-02 13:48:56 - browse：21

PHILADELPHIA — Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster drugs Ozempic and Wegovy, now also wants to be a major player in heart disease.

The landmark Select trial presented over the weekend — which showed Wegovy significantly cut the risk of heart complications — is just one of many efforts by the Danish drugmaker to expand into the cardiovascular space. It’s also developing several treatments specific to heart disease and is acquiring a medication for high blood pressure.

“We have a clear vision of being an established cardiovascular company, just as we see ourselves as leaders in diabetes and obesity,” Martin Lange, Novo’s executive vice president of development, said in an interview here at the American Heart Association conference.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Sports medicine is finally prioritizing gender equality
Next article： RaDonda Vaught to speak at CommonSpirit event on patient safety

WSS

The untold story of TV’s first prescription drug ad

Pfizer highlights cancer drugs it thinks could reignite investor interest

Lack of health data on LGBTQ+ people has serious consequences

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

How to fix the rural physician shortage in the U.S.

Biotech companies concerned about China biosecurity crackdown

leisure time

knowledge

Wikipedia

What does generative AI mean for health care? We asked experts

Stem cell biologist probes earliest stages of human development

Cancer drug shortages should be causing more outrage

Flu vaccine offering decent levels of protection this winter, new data show

Medical records are filled with copy

Streamlined flu vaccines recommended by FDA advisory panel

Peter Hotez and the public health issue of online harassment

Readout Newsletter: Ironwood, Pfizer, FogPharma updates

How one medical school became remarkably diverse

International team creates first chimeric human

hotspot

Why getting cancer drugs just got harder for rural patients

FogPharma raises $145 million in rare Series E round

FogPharma raises $145 million in rare Series E round

Change Healthcare cyberattack outage could last weeks

How to address the problem of discarded donor organs

Immune cells and nerve overgrowth may explain recurring UTI pain

explore

focus

focus

explore